Studies investigating the clinical validity and utility of tumor infiltrating lymphocyte count (CD8+, CD4+, T-helper, and dendritic cells) and PD-L1 expression as therapeutic biomarkers demonstrated their decreased infiltration in metastatic sites compared with primary lesions, which perhaps contribute to underlying ICI resistance [17, 18]. The gene discussed is CD8A; the disease is neoplasm.